Targeting KRAS G12C mutation in lung adenocarcinoma

Keyphrases

• Lung Adenocarcinoma 100%
• KRAS mutation 100%
• KRAS G12C mutation 100%
• Clinical Trials 50%
• Acquired Resistance 50%
• Specific Inhibitor 50%
• Mutant Protein 50%
• Targeted Therapy 50%
• Cancer Mortality 50%
• FDA-approved Drugs 50%
• Lung Cancer 50%
• Treatment Strategy 50%
• Patient Survival 50%
• Lung Cancer Cells 50%
• Cancer Causes 50%
• Combinational Therapy 50%
• Driver mutations 50%
• KRASG12C Inhibitors 50%
• Sotorasib 50%
• Indirect Strategy 50%

Medicine and Dentistry

• Lung Cancer 100%
• Lung Adenocarcinoma 100%
• Malignant Neoplasm 50%
• Clinical Trial 50%
• Cancer Cell 50%
• Targeted Therapy 50%
• Carcinogenesis 50%
• Mutant Protein 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Lung Cancer 100%
• Lung Adenocarcinoma 100%
• Clinical Trial 50%
• Malignant Neoplasm 50%
• Carcinogenesis 50%
• Mutant Protein 50%